Every earnings call for UNICHEMLAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.
UNICHEMLAB · 5 transcripts · Healthcare · latest Q3 FY17Unichem Laboratories Limited has 5 earnings calls on record here, a Healthcare company, most recently Q3 FY17. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue (Q3 FY17) ₹360 cr (+16% YoY); EBITDA (Q3 FY17) ₹44 cr (+30% YoY); PAT (Q3 FY17) ₹26 cr (+30% YoY). Q3 FY17 Revenue stood at Rs. 360 Crores, marking a 16% year-on-year growth.
Read full transcript & analysisStandalone Revenue (Q2 FY17) 227 Crores (+18% YoY); EBITDA (Q2 FY17) 39.6 Crores (+15% YoY). Total income from operations for Q2 FY17 was Rs. 368 Crores, marking a 19% YoY growth.
Read full transcript & analysisEBITDA 44 Crores. Total income from operations grew by 9.5% to Rs. 342 Crores.
Read full transcript & analysisConsolidated EBITDA ₹164 cr (+62% YoY); Consolidated EBITDA Margin 12.28%; Consolidated Net Profit (pre-exceptional) ₹111 cr. Consolidated FY16 Income from Operations grew 11% to Rs. 1335 Crores.
Read full transcript & analysisEBITDA ₹34 cr; Net Profit ₹23 cr. Q3 FY16 Turnover stood at Rs.306.3 Crores.
Read full transcript & analysis